铬酸酐

铬酸酐用途

【用途一】
其溶液用于镀铬
【用途二】
用于电镀、制高纯金属铬、染料、合成橡胶及油脂精制等
【用途三】
用作分析试剂和强氧化剂，也用于铬酸盐的制造
【用途四】
主要用于电镀工业，做自行车、缝纫机、手表、仪表、手电筒、日用五金等电镀铬的原料，也用于制高纯金属铬。是制造氧化铬绿和锌铬黄的原料；也是生产低温变换催化剂、高温变换催化剂及高压甲醇合成催化剂的原料。羊毛织物染色时用作媒染剂，印染工业中用作氧化剂。此外，还用于木材防腐。
【用途五】
本品是电镀铬的主要原料。电镀铬生产中，铬酐含量变动幅度较大，在50～500 g/L之间，主要控制适当的温度和电流密度，都能在平滑的镀件上获得光亮的镀层，它的溶液还能用于锌镀层钝化膜，使其防护性能提高。
【用途六】
氧化剂，光谱分析试剂，测定碳及磷，硬化油类及乙烯的纯化，氮肥生产中气体分析，金属全相分析，植保化验。铬盐的制造等。

点击显示

铬酸酐名称

[ CAS 号 ]:
1333-82-0

[ 中文名 ]:
三氧化铬

[ 英文名 ]:
chromium trioxide

[中文别名 ]:

[英文别名 ]:

Chromium Trioxide
MFCD00010952
CROMIUM TRIOXIDE
Chromic anhydride
Chromium Oxide
Chrormic trioxide
Chromium(VI) Oxide
Chromium (VI) Oxide
EINECS 215-607-8

铬酸酐物理化学性质

[ 密度 ]:
2.7

[ 沸点 ]:
330 °C

[ 熔点 ]:
196 °C (dec.)(lit.)

[ 分子式 ]:
CrO₃

[ 分子量 ]:
99.994

[ 闪点 ]:
250°C

[ 精确质量 ]:
99.925255

[ PSA ]:
51.21000

[ 外观性状 ]:
暗红色晶体或粉末

[ 储存条件 ]:
库房通风低温干燥,与可燃物、有机物、还原剂分开存放

[ 稳定性 ]:
Stable. Strong oxidizer. Reacts with most organic material in a violent and often explosive fashion. Moisture sensitive.

[ 水溶解性 ]:
Highly soluble

[ 凝固点 ]:
170~172℃

铬酸酐MSDS

详细MSDS(安全技术说明书)

铬酸酐毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: GB6650000

CAS REGISTRY NUMBER :: 1333-82-0

LAST UPDATED :: 199712

DATA ITEMS CITED :: 65

MOLECULAR FORMULA :: Cr-O3

MOLECULAR WEIGHT :: 100.00

WISWESSER LINE NOTATION :: CR2 O3

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Human

DOSE/DURATION :: 110 ug/m3

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 80 mg/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - cyanosis Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 58400 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 9260 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 127 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 14 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 20 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 17100 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 29 ug/m3/20H/90D-I

TOXIC EFFECTS :: Behavioral - muscle contraction or spasticity Lungs, Thorax, or Respiration - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - carbonic anhydrase

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Human

DOSE/DURATION :: 110 ug/m3/3Y-C

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors Lungs, Thorax, or Respiration - tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Implant

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 125 mg/kg

TOXIC EFFECTS :: Tumorigenic - Carcinogenic by RTECS criteria Tumorigenic - tumors at site of application

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3480 ug/m3/2H/1Y-I

TOXIC EFFECTS :: Tumorigenic - equivocal tumorigenic agent by RTECS criteria Sense Organs and Special Senses (Olfaction) - tumors

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Subcutaneous

DOSE :: 20 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 5 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - homeostasis Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - Central Nervous System

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 7500 ug/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 7500 ug/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

DOSE :: 8 mg/kg

SEX/DURATION :: female 8 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - body wall

TYPE OF TEST :: Specific locus test

TYPE OF TEST :: Specific locus test

TYPE OF TEST :: Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :: Mutation in mammalian somatic cells

TEST SYSTEM :: Rodent - hamster Ovary

REFERENCE :: CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980- Volume(issue)/page/year: 13,2053,1992 *** REVIEWS *** ACGIH TLV-TWA 0.05 mg(Cr)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 ACGIH TLV-Confirmed human carcinogen DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: TLV/BEI,1997 IARC Cancer Review:Animal Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 23,205,1980 IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 23,205,1980 IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 49,49,1990 IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 49,49,1990 IARC Cancer Review:Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 49,49,1990 TOXICOLOGY REVIEW 85DHAX "Medical and Biologic Effects of Environmental Pollutants Series," Washington, DC, National Academy of Sciences, 1972-77 Volume(issue)/page/year: Cr,22,1974 *** U.S. STANDARDS AND REGULATIONS *** MSHA STANDARD-air:TWA 0.5 mg(Cr)/m3 DTLVS* The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996 Volume(issue)/page/year: 3,35,1971 OSHA PEL (Gen Indu):CL 0.1 mg(CrO3)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1910.1000,1994 OSHA PEL (Construc):CL 0.1 mg(CrO3)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1926.55,1994 OSHA PEL (Shipyard):CL 0.1 mg(CrO3)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 29,1915.1000,1993 OSHA PEL (Fed Cont):CL 0.1 mg(CrO3)/m3 CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402) Volume(issue)/page/year: 41,50-204.50,1994 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-FINLAND;Carcinogen JAN 1993 OEL-FRANCE:TWA 0.05 mg/m3;STEL 0.1 mg/m3;Carcinogen JAN 1993 OEL-GERMANY;Carcinogen JAN 1993 OEL-RUSSIA:STEL 0.01 mg/m3;Skin JAN 1993 OEL-SWITZERLAND:TWA 0.05 mg/m3;STEL 0.1 mg/m3 JAN 1993 OEL IN BULGARIA, COLOMBIA, JORDAN, KOREA check ACGIH TLV OEL IN NEW ZEALAND, SINGAPORE, VIETNAM check ACGIH TLV *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH RECOMMENDED EXPOSURE LEVEL (REL) : NIOSH REL TO CHROMIUM(VI)-air:10H CA TWA 0.001 mg(Cr)/m3 REFERENCE : NIOSH* National Institute for Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda. Volume(issue)/page/year: DHHS #92-100,1992 NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 19430 No. of Facilities: 1253 (estimated) No. of Industries: 28 No. of Occupations: 44 No. of Employees: 20618 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 19430 No. of Facilities: 2873 (estimated) No. of Industries: 55 No. of Occupations: 65 No. of Employees: 68271 (estimated) No. of Female Employees: 11533 (estimated)

点击显示

铬酸酐安全信息

[ 符号 ]:

GHS03, GHS05, GHS06, GHS08, GHS09

[ 信号词 ]:
Danger

[ 危害声明 ]:
H271-H301 + H311-H314-H317-H330-H334-H340-H350-H361f-H372-H410

[ 警示性声明 ]:
P201-P260-P280-P303 + P361 + P353-P304 + P340 + P310-P305 + P351 + P338

[ 个人防护装备 ]:
Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges

[ 危害码 (欧洲) ]:
O:Oxidizingagent;T+:Verytoxic;N:Dangerousfortheenvironment;

[ 风险声明 (欧洲) ]:
R24/25;R26;R35;R42/43;R45;R46;R48/23;R50/53;R62;R9

[ 安全声明 (欧洲) ]:
S53-S45-S60-S61-S36/37/39-S28-S26-S22

[ 危险品运输编码 ]:
UN 1463 5.1/PG 2

[ WGK德国 ]:
3

[ RTECS号 ]:
GB6650000

[ 包装等级 ]:
II

[ 危险类别 ]:
5.1

[ 海关编码 ]:
2819100000

铬酸酐合成路线

详细合成路线

铬酸酐上下游产品

铬酸酐上游产品

铬酸酐下游产品

铬酸酐制备

1.硫酸法将重铬酸钠与硫酸加热熔融进行反应，反应结束后静置，分去硫酸氢钠，再冷却、出料制片、包装即制得铬酸酐。其反应式如下：

2.铬矿与纯碱和石灰石共热，再用浓硫酸处理而制得本品。

3.硫酸法、硝酸法、氟硅酸法及电解法等。工业上主要采用硫酸法。将无水重铬酸钠与硫酸在反应釜内混合后,加热至200℃进行熔融反应，得到熔融产物铬酐和硫酸氢钠，静置分层后，冷却即可。

4.取100g脱水后的无水重铬酸钠溶解于250mL水里并过滤，在搅拌下向透明的滤液里慢慢地加入400mL浓硫酸。因为过快地大量加入是非常危险的，所以加酸时必须注意温度的上升速度。加完之后加热时，则开始析出紫红色CrO3。放置24h后，将析出的结晶过滤，用浓硝酸反复洗涤若干次直至没有吸附的硫酸为止，然后干燥。

5.也可以用重铬酸钾代替重铬酸钠。取10g重铬酸钾溶解于100mL水中，慢慢地加入50mL95%硫酸，这时迅速发热，逐渐析出紫红色CrO3。放置24h，大部分针状结晶都析出来，用玻璃砂芯漏斗过滤，用硝酸洗涤数次以除去硫酸，充分干燥后放入玻璃瓶中保存。

点击显示

铬酸酐海关

[ 海关编码 ]: 2819100000

铬酸酐文献

Impairment of renal structure and function following heterogeneous chemical mixture exposure in rats.

Indian J. Exp. Biol. 52(4) , 332-43, (2014)

Renal structural and functional alterations following an exposure to a heterogeneous chemical mixture (HCM) of phthalic acid di butyl ester, 1, 2-dichlorobenzene, cadmium chloride and chromium trioxid...

[Improved methodology for quantitative determination of thiabendazole].

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho. Hokoku. (130) , 46-9, (2012)

The method prescribed in the 8th edition of Japan's Specifications and Standards for Food Additives (JSSFA) for the quantitative analysis of thiabendazole was improved by eliminating the use of toxic ...

Genotoxicity of tri- and hexavalent chromium compounds in vivo and their modes of action on DNA damage in vitro.

PLoS ONE 9(8) , e103194, (2014)

Chromium occurs mostly in tri- and hexavalent states in the environment. Hexavalent chromium [Cr(VI)] compounds are extensively used in diverse industries, and trivalent chromium [Cr(III)] salts are u...

更多文献

铬酸酐

铬酸酐用途

铬酸酐名称

铬酸酐物理化学性质

铬酸酐MSDS

详细MSDS(安全技术说明书)

铬酸酐毒性和生态

CHEMICAL IDENTIFICATION

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

铬酸酐安全信息

铬酸酐合成路线

详细合成路线

铬酸酐上下游产品

铬酸酐上游产品

铬酸酐下游产品

铬酸酐制备

铬酸酐海关

铬酸酐文献

相关化工产品/化学物质：

推荐生产厂家/供应商：

相关化合物